GURUFOCUS.COM » STOCK LIST » USA » NAS » Immix Biopharma Inc (NAS:IMMX) » Definitions » ROC %
Switch to:

Immix Biopharma (NAS:IMMX) ROC %

: -136,443.81% (As of Sep. 2022)
View and export this data going back to 2021. Start your Free Trial

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Immix Biopharma's annualized return on capital (ROC %) for the quarter that ended in Sep. 2022 was -136,443.81%.

As of today (2023-03-22), Immix Biopharma's WACC % is 7.18%. Immix Biopharma's ROC % is -374.44% (calculated using TTM income statement data). Immix Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Immix Biopharma ROC % Historical Data

The historical data trend for Immix Biopharma's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21
ROC %
-20.94 -10.49 -53.25

Immix Biopharma Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROC % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.07 -78.97 -1,027.58 -1,935.64 -136,443.81

Immix Biopharma ROC % Calculation

Immix Biopharma's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2021 is calculated as:

ROC % (A: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2020 ) + Invested Capital (A: Dec. 2021 ))/ count )
=-1.352 * ( 1 - -0.02% )/( (4.683 + 0.396)/ 2 )
=-1.3522704/2.5395
=-53.25 %

where

Immix Biopharma's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2022 is calculated as:

ROC % (Q: Sep. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2022 ) + Invested Capital (Q: Sep. 2022 ))/ count )
=-6.132 * ( 1 - -0.13% )/( (0.0050000000000026 + 0.0040000000000013)/ 2 )
=-6.1399716/0.0045000000000019
=-136,443.81 %

where

Invested Capital(Q: Jun. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19.088 - 0.977 - ( 18.402 - max(0, 0.977 - 19.083+18.402))
=0.0050000000000026

Invested Capital(Q: Sep. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17.395 - 0.646 - ( 16.917 - max(0, 0.646 - 17.391+16.917))
=0.0040000000000013

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immix Biopharma  (NAS:IMMX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Immix Biopharma's WACC % is 7.18%. Immix Biopharma's ROC % is -374.44% (calculated using TTM income statement data). Immix Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Immix Biopharma ROC % Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immix Biopharma (NAS:IMMX) Business Description

Immix Biopharma logo
Traded in Other Exchanges
N/A
Address
11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation. Its product candidate drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME.
Executives
Melissa Jane Buchan director 1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Helen C. Adams director 15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Ilya M Rachman director, officer: CEO and Chairman 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Carey Ng director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin officer: Scientific Co-Founder 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris director, officer: Chief Financial Officer 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross officer: CMO & Head of Clinical Dev. 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Jason Hsu director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Sean Senn 10 percent owner 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064